"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

A phase 3 trial did not support a transplant-based approach for patients who already achieved MRD negativity or a tandem transplant approach for those who did not achieve prior MRD negativity. In ...

Measurable residual disease (MRD) is a major prognostic factor in newly diagnosed multiple myeloma. An assessment of an MRD-guided consolidation strategy in patients who are eligible for autologous ...

Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant (ASCT) for patients with mantle cell lymphoma (MCL) in remission following ...

It is the first evidence that MCL patients in complete remission, with undetectable minimal residual disease (MRD), may be able to rely on highly effective standard treatments and avoid the rigors of ...

To continue the response they experienced with a first autologous stem‐cell transplant (ASCT) for their multiple myeloma, patients in this analysis received a second ASCT, with French investigators ...

With lower toxicity and equal efficacy, radioimmunotherapy is a better option than autologous stem cell transplant (ASCT) for relapsed /refractory follicular lymphoma consolidation, new data show.

Credit: BioLineRx. Aphexda is expected to be available in September 2023. The Food and Drug Administration (FDA) has approved Aphexda ™ (motixafortide) in combination with filgrastim (granulocyte ...

20-year-old Katie loves tutorial porn. The university student, who is using her first name only for privacy reasons, tells Mashable that it helped her to understand sex during a time where it ...

Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — Consolidation therapy with high-dose chemotherapy followed by hematopoietic stem cell transplant ...